Nasus Pharma (NSRX) Debt Ratio (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Debt Ratio came in at 4.01 in Q2 2025, up 59.59% on a QoQ basis from 2.51 in Q4 2024.
Nasus Pharma (NSRX) Debt Ratio (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Debt Ratio data on file, last reported at 4.01 in Q2 2025.
- Quarterly Debt Ratio changed N/A year-over-year to 4.01 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 4.01 (changed N/A YoY) and the FY2024 annual result came in at 2.51, changed N/A from the prior year.
- Debt Ratio rose to 4.01 in Q2 2025, from 2.51 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 4.01 in Q2 2025 to a low of 2.51 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.15 Bn | 634.39 Bn | 17.26 Bn | 0.24 |
| 2 | AbbVie | 469.47 Bn | 462.91 Bn | 12.70 Bn | 0.52 |
| 3 | Merck | 380.63 Bn | 373.49 Bn | 12.21 Bn | 0.42 |
| 4 | Novartis Ag | 302.58 Bn | 294.89 Bn | 11.24 Bn | 0.08 |
| 5 | Astrazeneca | 257.84 Bn | 252.94 Bn | 12.86 Bn | 0.25 |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | 0.66 |
| 7 | Gilead Sciences | 182.92 Bn | 179.74 Bn | 6.22 Bn | 0.58 |
| 8 | Pfizer | 161.16 Bn | 149.47 Bn | 10.94 Bn | 0.31 |
| 9 | Gsk | 105.59 Bn | 101.42 Bn | 8.24 Bn | -0.31 |
| 10 | Nasus Pharma | 29.72 Mn | 29.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.01 |
| Dec 31, 2024 | 2.51 |